Incyte's Opzelura Gets Positive CHMP Opinion for Moderate Atopic Dermatitis

What happened

Incyte announced that the CHMP has adopted a positive opinion for Opzelura (ruxolitinib cream) for treating adults with moderate atopic dermatitis in the EU. This is a regulatory step toward EU approval, which would expand Opzelura's market beyond current vitiligo and pediatric AD indications. The positive opinion comes as Incyte works to diversify away from its Jakafi dependency ahead of the 2028 patent cliff, with Opzelura revenue expected to grow at mid-teens or better. However, the stock already reflects significant optimism, trading at ~45x EV/EBITDA, and this news is unlikely to materially alter the fundamental challenges of payer pressure and competition. While a positive development, it does not resolve the core thesis risk that Incyte's non-Jakafi portfolio may not grow fast enough to offset the LOE impact.

Implication

Successful EU approval would support Opzelura's international revenue trajectory and help build the case for a smoother Jakafi transition. However, investors should monitor actual reimbursement and uptake in Europe, as well as ongoing CMS litigation in the U.S., before concluding the diversification story is de-risked.

Thesis delta

The positive CHMP opinion adds incremental validation to Opzelura's commercial potential in Europe but does not alter the fundamental risk/reward. The core thesis remains that Incyte trades at a premium multiple requiring flawless execution across Opzelura, tafasitamab, and payer negotiations, with limited margin of safety. This news modestly supports the bull case but does not close the gap between elevated expectations and the tangible risks of the 2028 patent cliff.